Abstract 1799P
Background
Metastatic castration resistant prostate cancer (mCRPC) patients (pts) with HRR alterations (HRR+) benefit from PARPi. We aimed to elucidate the RW outcomes and impact of streamlined access to a biomarker driven tx approach.
Methods
In a multicentre prospective mPCa cohort study, cell free DNA next generation sequencing (cfDNA NGS) was performed using accredited assays (BC Cancer, Foundation Medicine, Alberta panel). Time to CRPC was compared between HRR+ and negative/unknown status (HRR0) using log rank test. In olaparib tx pts, ≥50% PSA decline, radiographic progression free survival (rPFS), serious adverse events (SAE), and overall survival (OS) were examined.
Results
Of 119 pts, 41 (35%) were HRR+ (23 BRCA2, 14 ATM, 5 CDK12, 3 CHEK2, 2 PPP2R2A, 1 BRCA1, 1 PALB2). Median age at diagnosis was 64 yrs, 45% had Gleason ≥ 8, and 13% were non-caucasian. HRR+ pts had a shorter time to CRPC than HRR0 pts (13.7 vs 31.3 months; HR: 2.2; p=0.001). 28 HRR+ pts (19 BRCA2, 8 ATM, 1 BRCA1) received olaparib, demonstrating a trend towards improved OS from mCRPC compared to HRR+ pts without PARPi (38.1 vs 17.4 mo, p=0.20). In 9 HRR+ pts without PARPi, 7 had androgen receptor pathway inhibitor (ARPi) tx and taxane, 1 had ARPi, and 1 had docetaxel. 50% of pts received olaparib after ≥2 systemic tx lines. A longer OS trend was observed in pts receiving 1st line mCRPC olaparib tx than pts receiving olaparib in later tx lines (17.2 vs 11.1 mo, p=0.07). OS from mCRPC was similar in HRR0 and olaparib tx HRR+ pts (37.4 vs 38.1 mo, p=0.70). In olaparib tx pts, median OS post initiation was 11.7 mo, rPFS was 5.4 mo, 36% had ≥50% PSA decline, and 29% had ≥30 days tx beyond PSA progression (PCWG3 criteria). SAE occurred in 39%; 4 pts required transfusion for anemia. Of 8 pts receiving additional systemic tx, 6 had taxane- and 2 had platinum-based chemotherapy.
Conclusions
In this study of heavily pre-treated mPCa pts, RW rPFS and OS on olaparib were reduced compared to clinical trials. Similar OS was seen in olaparib tx HRR+ and HRR0 pts, despite historically poorer prognosis in HRR+ pts. These results demonstrate that a biomarker driven tx approach and earlier access to PARPi may improve outcomes in HRR+ pts.
Clinical trial identification
Editorial acknowledgement
This was an ESCR performed with AstraZeneca funding support and collaboration.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
S.M. Yip: Financial Interests, Personal, Advisory Board: Amgen, BMS, Novartis, Pfizer, Hoffman-La Roche, Ipsen; Financial Interests, Personal, Research Funding, Includes ad board/consultancy: Astellas, AstraZeneca, Merck, Bayer, Janssen; Financial Interests, Personal, Other, consultancy: Oncohelix. M. Kolinsky: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Merck, Janssen; Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, BMS, Eisai, Ipsen, Merck, Janssen; Financial Interests, Institutional, Research Grant: Janssen, AstraZeneca. T. Tucker: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Pfizer; Financial Interests, Institutional, Research Grant: Pfizer. P. Bose: Financial Interests, Personal, Ownership Interest, I am a co-founder and director in OncoHelix Inc: Oncohelix. T.A. Bismar: Financial Interests, Personal, Other, advisory role: xpherabio; Financial Interests, Institutional, Funding, funding support for fellow: AstraZeneca. D.Y.C. Heng: Financial Interests, Personal, Advisory Board: Pfizer, Merck, BMS, Ipsen, Novartis, AstraZeneca, Roche; Financial Interests, Personal, Steering Committee Member: Exilexis; Financial Interests, Institutional, Local PI: BMS, Pfizer, Ipsen. S. North: Financial Interests, Personal, Advisory Board, honoraria: Astellas, BMS, Janssen, Merck, Roche, Sanofi, Bayer, AstraZeneca; Financial Interests, Institutional, Local PI, per case funding: Sanofi, AstraZeneca, Ipsen, Astellas. N. Alimohamed: Financial Interests, Personal, Advisory Board: Bayer, Seagen, EMD Serono, BMS, Gilead. N.S. Basappa: Financial Interests, Personal, Advisory Board: Ipsen, Eisai, Pfizer, AstraZeneca, Janssen Inc, EMD Serono, Astellas, Bayer, BMS, Seagen, Takeda; Financial Interests, Institutional, Research Grant, Research Grant: Ipsen; Other, Other, Travel grant/support: Ipsen; Other, Other, Travel Grant/support: Eisai. K.N.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. S.E. El Hallani: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Full or part-time Employment: Alberta Precision Labs; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14